Foghorn Therapeutics (FHTX) Cash & Equivalents (2019 - 2026)

Foghorn Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $87.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 43.65% year-over-year to $87.7 million; the TTM figure through Mar 2026 stood at $87.7 million (up 43.65% YoY), while the FY2025 annual figure was $80.9 million, up 45.84% from the prior year.
• Cash & Equivalents was $87.7 million for Q1 2026 at Foghorn Therapeutics, up from $80.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $213.6 million in Q1 2022 to a low of $50.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $82.1 million across 5 years, with a median of $72.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 221.52% in 2022, then slumped 76.3% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then plunged by 30.97% to $55.5 million in 2024, then surged by 45.84% to $80.9 million in 2025, then increased by 8.39% to $87.7 million in 2026.
• The last three Cash & Equivalents figures came in at $87.7 million (Q1 2026), $80.9 million (Q4 2025), and $89.3 million (Q3 2025), per Business Quant data.